Platform insights are informed by the patient’s ecosytem. The platform products connect with 300+ consumer wearable devices and 940+ health systems and pharmacies.
Access a flexible, scalable, easy-to-use platform that supports multiple chronic conditions and can integrate with your current systems through technology partnerships.
Real-time care coordination requires real-time patient health data. Access patient information and recommended treatment modifications based on actual health trends and patterns. Get patient SMART Visit Reports containing clinical decision support for more productive care team visits.
Proactively address gaps in care, care transitions and readmissions, and gain deeper insights into how patients are doing.
The ability to collect and analyze patient health data allows providers to better coordinate care and support people throughout their care journeys.
As an FDA-cleared software as a medical device (SaMD) for type 1 and type 2 diabetes, BlueStar is reimbursable by CMS for RPM services while allowing patients to use whatever hardware device they choose.
In a prospective, randomized, controlled study, Quinn et al. (Diabetes Care, 2011) found that, individuals with type 2 diabetes whose A1C levels were > 7.5% at the time of enrollment, and who were randomized to use a mobile phone app to help them manage their diabetes in addition to usual care, improved A1C by an average 1.9%. Persons randomized to usual care alone improved A1C by an average of 0.7%. The difference between the intervention group and the control group was 1.2% (P < 0.001) over 12 months.
Methodology-Primary endpoint: change in A1C over one year. Randomization to one of four groups: (1) usual care (n=56), (2) usual care plus patient mobile app/access to web portal for diabetes management (n=23), (3) usual care, mobile app/portal for patient, plus provider access to raw patient data (n=22), and (4) usual care, mobile app/portal for patient, plus patient data tied to decision support for their physician (n=62). 213 patients enrolled; 163 included in the analysis. Limitations- Private insurance only. Study dropout rates required use of mixed-effects statistical modeling to impute missing observations
Welldoc funded a retrospective analysis with IBM Watson Health to test the relationship between A1C reduction and cost savings.
IBM Watson Health was provided starting and ending A1C data from 3,000+ BlueStar users with type 2 diabetes.
IBM Watson Health ran user data through their MarketScan Database, which captures claims data of more than 200 million individuals in the US.
Scale up to address the health conditions of the most vulnerable populations, while enabling care teams to have direct communication with those most in need of intervention.
With increased consumerization in healthcare, organizations benefit from improving the patient experience. Let us boost your numbers.